Evidence mapPaperPMID 40159541Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Optimizing antibody PET imaging: a comparative preclinical analysis of nanobody and minibody-like PET tracers.

Katty Zeven, Herlinde Dierick, Matthijs Sevenois, Henri Baudhuin, Laurent Navarro, Sonja Van den Block, Jelena Saliën, Karine Breckpot, Jessica Bridoux, Timo W M De Groof and 1 more

Abstract readComparative Study
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Katty ZevenMolecular Imaging and Therapy Research Group (MITH), Vrije Universiteit Brussel, Brussels, Belgium.
Herlinde DierickMolecular Imaging and Therapy Research Group (MITH), Vrije Universiteit Brussel, Brussels, Belgium.
Matthijs SevenoisMolecular Imaging and Therapy Research Group (MITH), Vrije Universiteit Brussel, Brussels, Belgium.
Henri BaudhuinAbscint NV, Liège, Belgium.
Laurent NavarroPrecirix NV, Brussels, Belgium.
Sonja Van den BlockMolecular Imaging and Therapy Research Group (MITH), Vrije Universiteit Brussel, Brussels, Belgium.
Jelena SaliënMolecular Imaging and Therapy Research Group (MITH), Vrije Universiteit Brussel, Brussels, Belgium.
Karine BreckpotTranslational Oncology Research Center (TORC), Laboratory for Molecular and Cellular Therapy (LMCT), Department of Biomedical Sciences, Vrije Universiteit Brussel, Brussels, Belgium.
Jessica BridouxMolecular Imaging and Therapy Research Group (MITH), Vrije Universiteit Brussel, Brussels, Belgium.
Timo W M De Groof *Molecular Imaging and Therapy Research Group (MITH), Vrije Universiteit Brussel, Brussels, Belgium. timo.de.groof@vub.be.ORCID http://orcid.org/0000-0001-6918-2955
Nick Devoogdt *Molecular Imaging and Therapy Research Group (MITH), Vrije Universiteit Brussel, Brussels, Belgium. nick.devoogdt@vub.be.

Funding

Fonds Wetenschappelijk Onderzoek 1230824NFonds Wetenschappelijk Onderzoek 12ZO723NFonds Wetenschappelijk Onderzoek 1S61021NFonds Wetenschappelijk Onderzoek 1S61023NKom op tegen Kanker Kom op tegen KankerStrategic Research Program Strategic Research ProgramWetenschappelijk Fonds Willy Gepts Wetenschappelijk Fonds Willy Gepts
6 · The paper itself

Abstract

purposePositron emission tomography remains the most important medical imaging technique for noninvasive imaging. Advances in radiotracer design, particularly those based on antibody(-formats), have broadened diagnostic applications. While minibodies and nanobodies stand out among antibody-type radiotracers due to their unique characteristics and pharmacokinetics, a direct comparison between these formats remains unexplored. In this study, we generated a so-called minabody, a minibody-like protein consisting of a nanobody fused to a CH3 domain, and compared it with its nanobody counterpart in vitro and in vivo upon labeling with various PET radionuclides.

methodsA previously developed human TIGIT-targeting nanobody was reformatted to a minabody format to allow head-to-head comparison of both formats. The minabody and nanobody formats were compared in vitro for binding, specificity and stability. The minabody and/or nanobody formats were labeled with copper-64, gallium-68 or fluor-18 for non-invasive imaging of human TIGIT-expressing tumors by PET/CT over time.

resultsThe minabody format showed higher binding affinities compared to the nanobody format. Despite lower binding affinity, the nanobody format outperformed the minabody format as PET imaging tracer showing higher specificity and allowing imaging of human TIGIT expression from 1 to 48 h post-injection upon labeling with copper-64. In addition, copper-64 showed superior tumor uptake and contrast for nanobody imaging compared to gallium-68 and fluor-18.

conclusionThis study describes the first head-to-head comparison between the minibody and nanobody format for PET imaging. Our results underscore the importance of considering both targeting vector format and the radionuclide to achieve accurate and high-quality PET imaging.

Indexed as

Positron-Emission TomographyPositron Emission Tomography Computed TomographySingle-Domain AntibodiesAnimalsCell Line, TumorCopper RadioisotopesHumansMiceRadioactive TracersRadiopharmaceuticalsCopper-64Copper RadioisotopesRadioactive TracersRadiopharmaceuticalsSingle-Domain AntibodiesMinabodyMinibodiesNanobodiesNuclear imagingPET imaging

Identifiers

PMID40159541
PMCPMC12316738

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.